Methods to assess the likelihood of dysplasia or esophageal adenocarcinoma
AssigneeMedical Research Council
InventorsRebecca Fitzgerald, Muhammad Alvi, Xinxue Liu
Life of this patent
Estimating the term…
Abstract
In some embodiments, a method for aiding assessment of the likelihood of dysplasia or esophageal adenocarcinoma being present in a subject can include (a) providing an esophagal sample from said subject (b) determining the methylation status of (i) SLC22A18, (ii) PIGR, (iii) GJA12 and (iv) RIN2 in said sample wherein if 2 or more of said genes are methylated then an increased likelihood of presence of dysplasia or esophageal is determined. The invention also relates to apparatus for same.
Claims19
A method for aiding assessment of the likelihood of dysplasia or esophagal adenocarcinoma being present in a subject, the method comprising
- (a) providing an esophagal sample from said subject
- (b) determining the methylation status of
- (i) SLC22A18,
- (ii) PIGR,
- (iii) GJA12 and
- (iv) RIN2
- in said sample
- wherein if 2 or more of said genes are methylated then an increased likelihood of presence of dysplasia or esophagal adenocarcinoma is determined.
An apparatus or system which is
- (a) configured to analyse an esophagal sample from a subject, wherein said analysis comprises
- (b) determining the methylation status of
- (i) SLC22A18,
- (ii) PIGR,
- (iii) GJA12 and
- (iv) RIN2
- in said sample,
- said apparatus or system comprising an output module,
- wherein if 2 or more of said genes are methylated then an increased likelihood of presence of dysplasia or esophagal adenocarcinoma is determined.
A method for aiding assessment of the likelihood of dysplasia or esophagal adenocarcinoma being present in a subject, the method comprising
- (a) providing an esophagal sample from said subject
- (b) determining the methylation status of
- (i) SLC22A18,
- (ii) PIGR,
- (iii) GJA12 and
- (iv) RIN2
- in said sample;
- comparing the methylation values of (b) to a reference standard,
- wherein if 2 or more of said genes are methylated at a level higher than the reference standard then an increased likelihood of presence of dysplasia or esophagal adenocarcinoma is determined.
(canceled)
Dependencies are inferred from the claim text.